Abstract
We exploited the emerging potential of gene therapy strategies to design a powerful therapeutic system that combines two key components—AAV vector and [6]-gingerol. In this study, we created an AAV2 construct expressing the proapoptotic protein BIM, which uses HSPG as its primary receptor, to target HSPG-overexpressing melanoma cells. This combination treatment showed promising results in vitro, inducing apoptosis in human melanoma cells. This new platform technology will make a significant contribution to numerous therapeutic applications, most notably for melanoma, including overcoming resistance to conventional anticancer therapies.
| Original language | English |
|---|---|
| Pages (from-to) | 194-199 |
| Number of pages | 6 |
| Journal | New Biotechnology |
| Volume | 37 |
| DOIs | |
| Publication status | Published - 2017 Jul 25 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biotechnology
- Bioengineering
- Molecular Biology
Cite this
}
Development of efficient adeno-associated virus (AAV)-mediated gene delivery system with a phytoactive material for targeting human melanoma cells. / Lee, John Hwan; Kim, Yoojin; Yoon, Ye Eun; Kim, Yong Jin; Oh, Seong Geun; Jang, Jae-Hyung; Kim, Eunmi.
In: New Biotechnology, Vol. 37, 25.07.2017, p. 194-199.Research output: Contribution to journal › Article
TY - JOUR
T1 - Development of efficient adeno-associated virus (AAV)-mediated gene delivery system with a phytoactive material for targeting human melanoma cells
AU - Lee, John Hwan
AU - Kim, Yoojin
AU - Yoon, Ye Eun
AU - Kim, Yong Jin
AU - Oh, Seong Geun
AU - Jang, Jae-Hyung
AU - Kim, Eunmi
PY - 2017/7/25
Y1 - 2017/7/25
N2 - We exploited the emerging potential of gene therapy strategies to design a powerful therapeutic system that combines two key components—AAV vector and [6]-gingerol. In this study, we created an AAV2 construct expressing the proapoptotic protein BIM, which uses HSPG as its primary receptor, to target HSPG-overexpressing melanoma cells. This combination treatment showed promising results in vitro, inducing apoptosis in human melanoma cells. This new platform technology will make a significant contribution to numerous therapeutic applications, most notably for melanoma, including overcoming resistance to conventional anticancer therapies.
AB - We exploited the emerging potential of gene therapy strategies to design a powerful therapeutic system that combines two key components—AAV vector and [6]-gingerol. In this study, we created an AAV2 construct expressing the proapoptotic protein BIM, which uses HSPG as its primary receptor, to target HSPG-overexpressing melanoma cells. This combination treatment showed promising results in vitro, inducing apoptosis in human melanoma cells. This new platform technology will make a significant contribution to numerous therapeutic applications, most notably for melanoma, including overcoming resistance to conventional anticancer therapies.
UR - http://www.scopus.com/inward/record.url?scp=85015339492&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85015339492&partnerID=8YFLogxK
U2 - 10.1016/j.nbt.2017.02.001
DO - 10.1016/j.nbt.2017.02.001
M3 - Article
C2 - 28179151
AN - SCOPUS:85015339492
VL - 37
SP - 194
EP - 199
JO - New Biotechnology
JF - New Biotechnology
SN - 1871-6784
ER -